SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced an extension to its longstanding agreement with PerkinElmer, which supplies chips for Agilent’s popular 2100 Bioanalyzer system.
“This agreement ensures that, for years to come, molecular biologists can continue to depend on the sample quality and high-fidelity data they obtain with the Agilent 2100 Bioanalyzer system”
Since its introduction in 1999, the 2100 Bioanalyzer system has become an integral part of molecular biology laboratories around the world. It is used in DNA sequencing, gene expression, DNA fragment analysis, quality control for protein-based drugs, and other applications.
“This agreement ensures that, for years to come, molecular biologists can continue to depend on the sample quality and high-fidelity data they obtain with the Agilent 2100 Bioanalyzer system,” said Dr. Knut Wintergerst, marketing and support manager for microfluidics at Agilent.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenue of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.
Contacts
Agilent Technologies Inc.
Victoria Wadsworth-Hansen, +1 408-553-2005
victoria.wadsworth-hansen@agilent.com
